Antibe Therapeutics Inc(Pre-Merger) ATBPF

Catalyst

[MasterAlgae]

The amalgamation was an expected event and that's why it did not have a catalyst effect on the market.

 

The market is also expecting a partnership, it is highly doubtful that there would be a buyout of a phase II drug when phase III trials have an average 62% success rate, that would be reckless.

 

A partnership announcement would be a catalyst that would indicate independent confirmation of potential future revenue related to the platform.
I don't think that new pipeline success would be much of a catalyst for institutions to risk capital either because the market/institutions have heard the H2S story for many, many years.

My guess is that from an institutional investor perspective we're at a  "Show-me, I'm from Missouri" point.

Once the amalgamation is signed - then the stage is set for confirmation of the H2S platform from a large pharma company(s?), then I believe institutional investors would be willing to "share the risk" and invest once they see that confirmation from a partnership.
"Going it alone" would not be a catalyst, I think that would be a stressful, expensive and hazardous trip.
 

[Actuarial]

There is one more thing Antibe can do before 346 PH3 - get rid of Citagenix.

[Daydream2]

Well said indeed. To add to your observations is the pending release of the latest animals test. Hopefully, they will announce those results anytime this month. However, in my view, I think they are late reporting them.     

[WalkOverTheStrt]

Agree with majority esp if Dan and team GIA but not: "I don't think that new pipeline success would be much of a catalyst for institutions to risk capital either because the market/institutions have heard the H2S story for many, many years.".  I've followed RNAI for years which has been in the works since the early 2000's and just like HS2 was on the back burner until